An Open-label, Single Arm, Phase I Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Advanced or Recurrent NSCLC

Trial Profile

An Open-label, Single Arm, Phase I Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Advanced or Recurrent NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs BPI-7711 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Beta Pharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top